melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 

theraTRACE

Melior Pharmaceuticals

 

   

              

 

              

 

 

                  

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery collaborative discoveries

 
   

Underlined name denotes Melior contributor

 

Translating Alcohol Research:  Opportunities and Challenges

Batman AM, Miles MF

Alcohol Research 2015;37(1):7-14

 

melior

ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice. Naydenov AV, Horne EA, Cheah CS, Swinney K, Hsu KL, Cao JK, Marrs WR, Blankman JL, Tu S, Cherry AE, Fung S, Wen A, Li W, Saporito MS, Selley DE, Cravatt BF, Oakley JC, Stella N. Neuron. 2014 Jul 16;83(2):361-71.

melior
Anticonvulsant activity of pregabalin in the maximal electroshock-induced seizure assay in α2δ1 (R217A) and α2δ2 (R279A) mouse mutants. Lotarski S, Hain H, Peterson J, Galvin S, Strenkowski B, Donevan S, Offord J. Epilepsy Res. 2014 Jul;108(5):833-42.
melior
ADX71441, a novel, potent and selective positive allosteric modulator of the GABA(B) receptor, shows efficacy in rodent models of overactive bladder. Kalinichev M, Palea S, Haddouk H, Royer-Urios I, Guilloteau V, Lluel P, Schneider M, Saporito M, Poli S. Br J Pharmacol. 2014 Feb;171(4):995-1006.
melior
Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker. Kaur ZP, Ochman AR, Mayer JP, Gelfanov VM, DiMarchi RD. ACS Chem Biol. 2013 Aug 16;8(8):1822-9.
melior
Possible therapeutic effect of trilostane in rodent models of inflammation and nociception. Tung D, Ciallella J, Hain H, Cheung PH, Saha S. Curr Ther Res Clin Exp. 2013 Dec;75:71-6.
melior
Novel anti-inflammatory effects of doxazosin in rodent models of inflammation. Tung D, Ciallella J, Cheung PH, Saha S. Pharmacology. 2013;91(1-2):29-34.
melior
Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion. Roix JJ, DeCrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R. Diabetes Obes Metab. 2012 Apr;14(4):329-34.
melior
Synthesis and pharmacological evaluation of N-(-3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl) methanesulfonamide (LP-261), a potent antimitotic agent.  Shetty RS, Lee Y, Lui B, Husain A, Joseph RW, Lu Y, Nelson D, Mihelcic J, Chao W, Moffett KK, Shumacher A, Flubacher D, Stojanovic A, Bukhtiyarova M, Williams K, Lee KJ, Ochman AR, Saporito MS, Moore WR, Flynn GA, Dorsey BD, Springman EB, Fujimoto T, Kelly MJ. J Med Chem. 2011 Jan 14; 54(1): 179-200.
melior
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Tung D, Cheung PH, Kaur P, Foreman O, Kavirayani A, Hain HS, Saha S. Pharmacology. 2011;88(1-2):100-13.
melior
Novel anti-inflammatory effects of repaglinide in rodent models of inflammation. Tung D, Cheung PH, Ciallella J, Saha S. Pharmacology. 2011;88(5-6):295-301.
melior
Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Fritzinger DC, Hew BE, Lee JQ, Newhouse J, Alam M, Ciallella JR, Bowers M, Gorsuch WB, Guikema BJ, Stahl GL, Vogel CW. Adv Exp Med Biol. 2008;632:293-307

melior

Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronapthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. Hudkins RL, Diebold JL, Tao M, Josef KA, Park CH, Angeles TS, Aimone LD, Husten J, Ator MA, Meyer SL, Holskin DP, Durkin JT, Fedorov AA, Fedorov EV, Almo SC, Mathiasen JR, Bozyczko-Coyne D, Saporito MS, Scott RW, Mallamo JP. J Med Chem. 2008 Sep 25; 51(18):5680-9.

melior

An extensive phenotypic characterization of the hTNFalpha transgenic mice. Hayward MD, Joes BK, Saparov A, Hain HS, Trillat AC, Bunzel MM, Coron A, Li-Wang B, Strenkowski B, Giordano C, Shen H, Arcamone E, Weidlick J, Vilensky M, Tugusheva M, Felkner RH, Campbell W, Rao Y, Grass DS, Buiakova O.  BMC Physiol. 2007 Dec 10; 7:13.
melior

Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase. Sentman ML, Granstrom M, Jakobson H, Reaume A, Basu S, Marklund SL. J Biol Chem. 2006 Mar 17; 281(11):6904-9.

melior

Back to top of page